Agenda

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Assess the role of co-pay accumulators in patient benefit management.
• Contrast best practices regarding use of third-party financial support, including foundation programs, co-pay cards, and patient assistance programs.
• Discuss cost control and management opportunities from patient through payer.

Learning Objectives:

• Analyze proposed areas of reform, including Medicare Part D pharmacy direct and indirect remuneration, Medicare Part D rebates, and Medicare Part B.
• Outline the effects on Medicare Part D protected classes.
• Assess the Medicare 340B program, including legal challenges and impacts.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process

Learning Objectives:

• Outline components of the FDA’s Biosimilar Action Plan.
• Discuss current status of plan and changes that have occurred since introduction.
• Review current slate of biosimilar medications and the action plan’s proposed impact on industry segment growth.

Learning Objectives:

• Describe the key trends that are impacting employer plan sponsors in managing specialty drugs
• Recognize what matters to them when partnering with specialty pharmacies
• Identify what employer models are having an impact on costs and patient outcomes

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Discuss the SPC Board partnership and current state of the Certified Specialty Pharmacist Program, including industry acceptance.
• Report results of the Specialty Pharmacy Satisfaction Survey, focused on multiple stakeholder perspectives.

Learning Objectives:

• Review key pharmacogenomics trends and case examples of its use in specialty pharmacy practice.
• Predict what the future holds for specialty pharmacy and artificial intelligence.
• Propose how technology and specialty pharmacy can maintain a synergistic model to benefit all stakeholders.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Describe the referral management process and steps to receipt of referral.
• Identify points of confusion related to intake and how to surmount challenges.
• Compare best practices in specialty pharmacy–prescriber relationships to decrease time to fill.

Learning Objectives:

• Recognize regulations affecting pharmacy operations, including prescription drug management programs, nonresident licensure, and accreditation.
• Formulate key steps a pharmacy can take to ensure compliance with aforementioned regulations.
• Discuss best practices of specialty pharmacies that have ensured both compliance and efficiency in gaining compliance.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Review updates to prescription handling and cold chain management standards.
• Discuss best practices to comply with the Drug Supply Chain Security Act.
• Describe advancements in packaging, returns handling, and other areas of the fulfillment process.

Learning Objectives:

• Describe examples of how AI can be used to gain insights across a patient journey receiving specialty medications.
• Explain the state of the art for using artificial intelligence and interactive robots for patient engagement and revealing challenges of symptom management and patient behaviors (outside of a clinical environment) and factors that may cause adherence issues.
• Identify how to bring these models to market for pilots and ultimately to deploy in the real world with patients.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Recognize key data elements shared across the specialty pharmacy industry.
• Identify elements of standardization attempted by each stakeholder on the panel.
• Describe challenges to further standardization of data and ways to overcome them.

Learning Objectives:

• Review policy priorities and position statements supported by NASP.
• Outline congressional and regulatory action.
• Illustrate the role of the NASP Political Action Committee, along with other NASP grassroots efforts.

Meeting Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Assess the role of co-pay accumulators in patient benefit management.
• Contrast best practices regarding use of third-party financial support, including foundation programs, co-pay cards, and patient assistance programs.
• Discuss cost control and management opportunities from patient through payer.

Learning Objectives:

• Discuss best-case relationships between specialty pharmacies and manufacturers, including clinical programs.
• Illustrate approaches to specialty pharmacy contracting, including key takeaways for capabilities and cost management.
• Review case examples of high-performing limited distribution models and the pros and cons across the supply chain.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Recognize key data elements shared across the specialty pharmacy industry.
• Identify elements of standardization attempted by each stakeholder on the panel.
• Describe challenges to further standardization of data and ways to overcome them.

Learning Objectives:

• Assess the landscape of health-system specialty pharmacy growth.
• Propose models of efficiency related to health-system, integrated delivery, or hybrid models of care.
• Discuss practice pearls for managing transition of care from diagnosis through outpatient journey, as well as foundational inquiries about the process of building a health-system specialty pharmacy.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Review multistakeholder considerations for rare disease therapy management, including accreditors, specialty pharmacies, payers, and geneticists.
• Examine the impact of rare disease therapies on each of the associated stakeholders using case studies.
• Discuss best practices for handling and managing rare disease therapies within the specialty pharmacy continuum.

Learning Objectives:

• Review key pharmacogenomics trends and case examples of its use in specialty pharmacy practice.
• Predict what the future holds for specialty pharmacy and artificial intelligence.
• Propose how technology and specialty pharmacy can maintain a synergistic model to benefit all stakeholders.

Learning Objectives:

• Define the role technology plays in speed to therapy.
• Identify the challenges in specialty prescribing.
• Articulate the outcomes seen from use of technology solutions in specialty prescribing.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Meeting Objectives:

• Evaluate the response from the Trump administration related to direct and indirect remuneration fees and the impact on specialty practice.
• Examine the historical level of congressional engagement.
• Apply tactics for pharmacy advocacy: What more can you do?

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Review of trends leading to the need for differentiation to attract attention of partners
• Describe key components of innovative care models where high-quality, cost-effective care is being rewarded with network access – both payer and pharmacy
• Illustrate steps specialty pharmacies can take to capture the attention of forward-thinking contract programs

Learning Objectives:

• Review related concepts and case examples of value-based care.
• Analyze key learnings from specialty pharmacy involvement in outcomes management and true value-based care.
• Identify key areas for specialty pharmacy growth to aid in this area.

Learning Objectives:

• Examine current standards of care within the disease area.
• Identify new agents approved over the past 12 months.
• Examine clinical pearls and best practices for clinically managing patients within the disease process.

Learning Objectives:

• Recognize regulations affecting pharmacy operations, including prescription drug management programs, nonresident licensure, and accreditation.
• Formulate key steps a pharmacy can take to ensure compliance with aforementioned regulations.
• Discuss best practices of specialty pharmacies that have ensured both compliance and efficiency in gaining compliance.

Learning Objectives:

• Differentiate core and enhanced specialty pharmacy offerings.
• Compare different service models, including internal and external hub service providers.
• Illustrate successful enhanced service programs and the value afforded to the patient journey, including staffing models with nursing.

Breakfast

Welcome & Introductions

Sterile Compounding Regulatory Climate, Accreditation, Data, Patient Satisfaction

Break

General Operations - Referral Flow, Staffing Roles, Compliance, Patient Oversight, Infusion Devices/Standards, Management of Home Environment

Lunch

Reimbusement - Reimbursement Commercial, Medicare, Medicaid, Challenges 

Government Affairs - Overview of current events related to legislation

Closing remarks and Adjourn

Intake, Fulfillment, Outcomes

Inflammatory Diseases

Osteoporosis

Break

Oncology

Transplant

Infertility

Part 1 Q & A

Lunch Break (Including Part 1 Q & A)

Multiple Sclerosis & Neurological Conditions

Hep C, HIV, CF

Break

Pulmonary Arterial Hypertension & Cardiology

RSV

Growth Hormone

Immunoglobulins

Hemophilia

Part 2 Q & A

Adjournment